Peptide database
7 entries. Every claim cited. Evidence graded by tier. Filtered by FDA compounding status.
Vendor-neutral reference on AOD-9604 (Tyr-hGH 177-191, the lipolytic fragment of GH): the Heffernan mouse data, the six Metabolic Pharmaceuticals human trials and the failed 24-week Phase 2b obesity efficacy trial, safety summary, and April 2026 Category 1 reclassification. Last reviewed May 2026.
Vendor-neutral reference on BPC-157: mechanism, the 3 published human studies, Category 1 reclassification (April 2026), and what Peter Attia and Andrew Huberman have actually said. Last reviewed May 2026.
Vendor-neutral reference on GHK-Cu (glycyl-histidyl-lysine copper): Pickart's 1973 isolation, gene expression data, the Leyden facial cream trial, why topical evidence does not transfer to injectable use, and current regulatory status. Last reviewed May 2026.
Vendor-neutral reference on sermorelin acetate (GHRH 1-29): mechanism, the pediatric and elderly human RCT data, Geref FDA approval and 2008 withdrawal, current 503A compounding status, and WADA status. Last reviewed May 2026.
Vendor-neutral reference on TB-500 (Ac-LKKTETQ thymosin β4 fragment): mechanism, the animal data, why full-length thymosin β4 trials don't transfer to the fragment, Category 1 reclassification (April 2026), and WADA status. Last reviewed May 2026.
Vendor-neutral reference on tesamorelin (Egrifta/Egrifta SV/Egrifta WR): mechanism, the NEJM Falutz pivotal trial, NAFLD data, the November 2010 FDA approval, the March 2025 Egrifta WR F8 reformulation, and WADA status. Last reviewed May 2026.
Vendor-neutral reference on thymosin alpha-1 (thymalfasin / Zadaxin): mechanism, the hepatitis B Phase 3 trials, ETASS severe sepsis trial, COVID-19 data, why Zadaxin is approved in 35+ countries but not the US, and the April 2026 Category 1 reclassification. Last reviewed May 2026.